Experimental MLN9708 is the first oral proteasome inhibitor, and it has shown itself to be highly active in a phase I/II clinical trial that enrolled 65 patients with newly diagnosed multiple myeloma.
Investigators reported that 92% responded to an all-oral regimen combining MLN9708 with lenalidomide (Revlimid) and dexamethsone. This included 55% with at least a very good partial response and 23% in complete response. A phase III trial is planned
Patrice Wendling interviewed Dr. Shaji K. Kumar on findings he presented at the annual meeting of the American Society of Hematology.